资源描述：
《重组人血管内皮抑制素联合顺铂和博来霉素治疗肺癌恶性胸腔积液的效果比较.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。
1、重组人血管内皮抑制素联合顺钳和博来霉素治疗肺癌恶性胸腔积液的效果比较［摘耍］目的观察重组人血管内皮抑制素联合顺釦和博来霉素治疗肺癌恶性胸腔积液的近期效果及安全性。方法2011年10月〜2013年10月，将73例肺癌伴恶性胸腔积液的患者经胸腔内置中心静脉导管排尽积液后随机分为A、B组。A组37例给予胸腔内灌注重组人血管内皮抑制素30ing+顺钳40mg；B组36例给了胸腔内灌注重组人血管内皮抑制素30mg+博来霉素粉针60mg,两组均每周给药1次，连续给药3周。评价两组患者胸腔积液减少量的近期疗效、Karnofsky体力状况评分、不良反应发生率及生存率
2、。结果胸腔积液减少量的近期疗效：A组的总有效率为72.97%,B组为88.89%,两组比较，差异无统计学意义(x2=2.98,P>0.05)。A组的KPS体力状况评分改善率为37.84%,B组为61.11%,两组比较，差异有统计学意义(x2=3.87,P0.05)o两组的6个月生存率(A组为86.49%,B组为94.44%)差异无统计学意义(x2=0・57,P>0.05),1年生存率(A组为54.05%,B组为77.78%)差异有统计学意义(x2=4.56,P<0.05)o结论重组人血管内皮抑制素联合顺釦和博来霉素治疗肺癌恶性胸腔积液均具有较好的效果
3、，且不良反应少。［关键词］重组人血管内皮抑制素；顺钳；博来霉素；恶性胸腔积液［中图分类号］R734.2［文献标识码］A［文章编号］1674-4721(2015)07(b)-0118-04[Abstract]ObjectiveToobservetheshort-termcurativeeffectandsafetyofrecombinanthumanendostatincombinedwithcisplatinandbleomycininthetreatment,ofmalignantpleuraleffusioninducedbylungcancer
4、.MethodsFromOctober2010toOctober2013,73patientswithlungcancercomplicatedwithmalignantpleuraleffusionwererandomlydividedintogroupAandgroupBaftercompletedischargeofeffusionbyimplantingcentralvenouscatheterinthoraciccavity.37patientsingroupAweregivenpleuralinfusionof30mgrecombinan
5、thumanendostatin+40mgofcisplatinwhile36patientsingroupBweregivenpleuralinfusionof30mgofrecombinanthumanendostatin+60mgofbleomycininjection.Thedrugwasadministeredonceaweekforcontinuous3weeks.Short-termcurativeeffectofdecreasedvolumeofpleuraleffusion,K且rnofskyperformaneescore,the
6、incidencerateofadversereactionandsurvivalratewasassessedbetweentwogroupsofpatients.ResultsShort-termcurativeeffectofdecreasedvolumeofpleuraleffusion：totaleffectiverateingroupAwas72.97%,whileit.was88.89%ingroupB,andtherewasnostatisticaldifferencebetweentwogroups(x2=2.98,卩＞0.05)•
7、TheimprovementrateofKPSphysicalconditionscorewas37.84%ingroupA,whileitwas61.11%,ingroupB,andtherewasastatisticaldiffereneebetweentwogroups(x2=3.87,P0.05).Therewasnostatisticaldifferenceof6~monthsurvivalrate(itwas86.49%ingroupAand94.44%ingroupB)(x2=0.57,P>0.05)；therewasastatisti
8、caldifferenceof1-yearsurvivalrate(itwas54.05%ingroupAa
